5 completed, 5 unknown, 4 recruiting, 1 terminated. 15 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 5, Unknown 5, Recruiting 4, Terminated 1 |
| Phase 2 | 4 | Unknown 2, Completed 1, Terminated 1 |
Follow Malignant Pleural Effusion: new trials by email Literature Review of Malignant Pleural Effusion trials Research Report on Malignant Pleural Effusion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 - Malignant Pleural Effusion, Malignant Mesothelioma | Phase 1 | Recruiting | David Bartlett, MD | 10 | 2026-06-03 | 2026-08-04 |
| Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2) - Malignant Pleural Effusion, Malignant Mesothelioma | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 10 | 2026-05-01 | 2026-04-07 |
| A Study of MT027 in Patients with Pleural Malignant Tumors MT027 cells suspension - Advanced Malignant Solid Tumor, Malignant Pleural Effusion | Phase 1 | Recruiting | Suzhou Maximum Bio-tech Co., Ltd. | 18 | 2024-05-15 | 2024-12-10 |
| Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer Tocilizumab - Malignant Pleural Effusion, Malignant Ascites | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 12 | 2024-01-30 | 2025-05-22 |
| OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. PITAC - Malignant Pleural Effusion, Pleural Neoplasms | Phase 1 | Unknown | Odense University Hospital | 20 | 2023-09-15 | 2024-05-20 |
| A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion JMKX000197 - Malignant Pleural Effusion | Phase 1 | Unknown | Jemincare | 78 | 2023-05-22 | 2023-06-28 |
| A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion bevacizumab and camrelizumab - Malignant Pleural Effusion | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital of Zhengzhou University | 55 | 2022-08-01 | 2022-04-15 |
| Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma RSO-021 - Malignant Pleural Effusion, Malignant Pleural Mesothelioma | Phase 1 / Phase 2 | Completed | RS Oncology LLC | 50 | 2022-03-31 | 2026-07-24 |
| A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion SCB-313 - Malignant Pleural Effusion | Phase 1 | Completed | Sichuan Clover Biopharmaceuticals, Inc. | 14 | 2020-01-08 | 2022-05-06 |
| Comparison of the Effectiveness of Povidone-Iodine Alone to Povidone-Iodine-Tetracycline Combination CHEMICAL PLEURODESIS WITH POVIDONE-IODINE-TETRACYCLINE COMBINATION, CHEMICAL PLEURODESIS WITH POVIDONE-IODINE ALONE - Malignant Pleural Effusion | Phase 1 | Unknown | University College Hospital, Ibadan | 62 | 2019-06-20 | 2020-11-05 |
| A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion Talimogene laherparepvec (TVEC), Nivolumab - Malignant Pleural Effusion, Stage IV Metastatic Cancer | Phase 1 / Phase 2 | Terminated | UNC Lineberger Comprehensive Cancer Center | 1 | 2019-03-06 | 2021-04-20 |
| A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites BSG-001 - Malignant Pleural Effusion, Malignant Ascites | Phase 1 / Phase 2 | Unknown | BioSyngen Pte Ltd | 58 | 2019-01-01 | 2018-11-08 |
| Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion AdV-tk + valacyclovir - Malignant Pleural Effusion, Lung Cancer | Phase 1 | Completed | Candel Therapeutics, Inc. | 19 | 2013-10-01 | 2023-08-25 |
| Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer gemcitabine hydrochloride, carboplatin, bortezomib - Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2002-09-01 | 2013-01-23 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu recombinant interleukin-12, ABI-007/carboplatin/trastuzumab - Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 1999-08-01 | 2013-02-28 |
Pleural Effusion, Malignant (15) · Mesothelioma, Malignant (4) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Mesothelioma (2) · Neoplasm Metastasis (2) · Adenocarcinoma, Follicular (1) · Adrenocortical Carcinoma (1) · Anus Neoplasms (1) · Appendiceal Neoplasms (1) · Bile Duct Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Islet Cell (1)
Neoplasms (15) · Neoplasms by Site (15) · Pleural Diseases (15) · Respiratory Tract Diseases (15) · Respiratory Tract Neoplasms (15) · Thoracic Neoplasms (15) · Pleural Effusion (14) · Pleural Neoplasms (14) · Lung Diseases (8) · Adenoma (6) · Lung Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms, Mesothelial (5) · Mesothelioma (3)
Interleukin-2 (2) · Pharmaceutical Preparations (2) · aldesleukin (2) · Bevacizumab (1) · Bortezomib (1) · Carboplatin (1) · Gemcitabine (1) · Interleukin-12 (1) · Interleukin-12 Subunit p35 (1) · Nivolumab (1) · Pleurodesis (1) · Povidone-Iodine (1) · Thiostrepton (1) · Trastuzumab (1) · Valacyclovir (1)
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (2) · National Cancer Institute (NCI) (2) · BioSyngen Pte Ltd (1) · Candel Therapeutics, Inc. (1) · David Bartlett, MD (1) · Jemincare (1) · Odense University Hospital (1) · RS Oncology LLC (1) · Sichuan Clover Biopharmaceuticals, Inc. (1) · Suzhou Maximum Bio-tech Co., Ltd. (1) · The First Affiliated Hospital of Zhengzhou University (1) · UNC Lineberger Comprehensive Cancer Center (1) · University College Hospital, Ibadan (1)
United States (7) · China (3) · Australia (1) · Denmark (1) · Nigeria (1) · United Kingdom (1)
Patrick Wagner, MD (2) · Angela Davies (1) · Charu Aggarwal, MD (1) · David Bartlett, MD (1) · Feng Wang (1) · James Spicer, MD (1) · Jared Weiss, MD (1) · Jianying Huang (1) · Lietao Li, MD (1) · William Carson (1)
N01CM17101 (1), U01CA076576 (1)